Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $210 and keeps an In Line rating on the shares after the company reported a “solid” Q1 beat and raised FY26 guidance. The firm sees updated guidance as “achievable with potential upside,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $225 from $220 at Jefferies
- Midday Fly By: Apple names new CEO, Amazon ups investment in Anthropic
- Early notable gainers among liquid option names on April 21st
- Quest Diagnostics: Sustained Volume Growth and Upgraded Revenue Outlook Justify Premium Valuation and Buy Rating
- Quest Diagnostices reports Q1 adjusted EPS $2.50, consensus $2.37